Tekla Life Sciences Investors
Tekla Life Sciences Investors (HQL) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Tekla Life Sciences Investors (HQL), featuring income statements, balance sheets, and cash flow data.
Tekla Life Sciences Investors (HQL) Income Statement & Financial Overview
Review Tekla Life Sciences Investors HQL income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $1.91M | $2.07M | $29.56M | $9.82M |
| Cost of Revenue | $0.00 | $0.00 | $2.59M | $2.65M |
| Gross Profit | $1.91M | $2.07M | $26.97M | $7.17M |
| Gross Profit Ratio | $1.00 | $1.00 | $0.91 | $0.73 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $3.18M | $2.72M | $0.00 | $1.44M |
| Operating Expenses | $3.18M | $2.72M | $38.42M | $15.94M |
| Total Costs & Expenses | $3.18M | $2.72M | $41.01M | -$23.98M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $1.27M | $653334.00 | $43812.00 | $470374.00 |
| EBITDA | $0.00 | $100.51M | -$11.45M | $34.27M |
| EBITDA Ratio | $0.00 | $48.67 | -$0.39 | $3.44 |
| Operating Income | -$1.27M | -$653336.00 | -$11.45M | $33.80M |
| Operating Income Ratio | -$0.66 | -$0.32 | -$0.39 | $3.44 |
| Other Income/Expenses (Net) | $36.31M | $50.91M | -$2985.00 | $1294.00 |
| Income Before Tax | $35.04M | $50.26M | -$11.45M | $33.80M |
| Income Before Tax Ratio | $18.30 | $24.33 | -$0.39 | $3.44 |
| Income Tax Expense | $0.00 | $0.00 | -$43812.00 | -$470374.00 |
| Net Income | $35.04M | $50.26M | -$11.45M | $33.80M |
| Net Income Ratio | $18.30 | $24.33 | -$0.39 | $3.44 |
| EPS | $1.22 | $1.84 | -$0.43 | $1.29 |
| Diluted EPS | $1.22 | $1.84 | -$0.43 | $1.29 |
| Weighted Avg Shares Outstanding | $28.77M | $27.35M | $26.79M | $26.21M |
| Weighted Avg Shares Outstanding (Diluted) | $28.77M | $27.35M | $26.79M | $26.21M |
Over the last four quarters, Tekla Life Sciences Investors achieved steady financial progress, growing revenue from $9.82M in Q2 2023 to $1.91M in Q4 2024. Gross profit stayed firm with margins at 100% in Q4 2024 versus 73% in Q2 2023. Operating income totaled -$1.27M in Q4 2024, maintaining a -66% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $0.00. Net income dropped to $35.04M, with EPS at $1.22. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan